Blood pressure drug shows promise against resistant ovarian cancer

NCT ID NCT06815497

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the blood pressure drug telmisartan to standard chemotherapy can help people with ovarian cancer that no longer responds to platinum-based treatments. About 33 adults with this type of cancer will receive the combination, and researchers will measure how long the cancer stays under control compared to past patients. The goal is to find a better way to manage the disease when standard options have failed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dartmouth Hitchcock

    RECRUITING

    Lebanon, New Hampshire, 03756, United States

    Contact

    Contact

  • Dartmouth-Hitchcock Manchester

    RECRUITING

    Manchester, New Hampshire, 03104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact